Company Analysis Emergent BioSolutions Inc.
1. Summary
Advantages
- Price (6.6 $) is less than fair price (8.67 $)
- The stock's return over the last year (-29.18%) is higher than the sector average (-47.49%).
- The company's current efficiency (ROE=-33.67%) is higher than the sector average (ROE=-83.32%)
Disadvantages
- Dividends (0%) are below the sector average (1.28%).
- Current debt level 47.76% has increased over 5 years from 34.82%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Emergent BioSolutions Inc. | Healthcare | Index | |
---|---|---|---|
7 days | -0.5% | -9.9% | 0.2% |
90 days | 40.7% | -45.7% | 15.8% |
1 year | -29.2% | -47.5% | 11.6% |
EBS vs Sector: Emergent BioSolutions Inc. has outperformed the "Healthcare" sector by 18.31% over the past year.
EBS vs Market: Emergent BioSolutions Inc. has significantly underperformed the market by -40.81% over the past year.
Stable price: EBS is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: EBS with weekly volatility of -0.5612% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.6 $) is lower than the fair price (8.67 $).
Price significantly below the fair price: The current price (6.6 $) is 31.4% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (18.1) is lower than that of the sector as a whole (52.65).
P/E vs Market: The company's P/E (18.1) is lower than that of the market as a whole (61.84).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.02) is lower than that of the sector as a whole (10.86).
P/BV vs Market: The company's P/BV (1.02) is lower than that of the market as a whole (20.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.4837) is lower than that of the sector as a whole (4.03).
P/S vs Market: The company's P/S indicator (0.4837) is lower than that of the market as a whole (15.97).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (26.3) is higher than that of the sector as a whole (16.29).
EV/Ebitda vs Market: The company's EV/Ebitda (26.3) is higher than that of the market as a whole (18.41).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -32.49% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-32.49%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-8.87%).
5.4. ROE
ROE vs Sector: The company's ROE (-33.67%) is higher than that of the sector as a whole (-83.32%).
ROE vs Market: The company's ROE (-33.67%) is lower than that of the market as a whole (42.62%).
5.5. ROA
ROA vs Sector: The company's ROA (-11.86%) is lower than that of the sector as a whole (6.38%).
ROA vs Market: The company's ROA (-11.86%) is lower than that of the market as a whole (23.26%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.57%) is lower than that of the sector as a whole (15.07%).
ROIC vs Market: The company's ROIC (7.57%) is lower than that of the market as a whole (9.15%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.28%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.5.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription